<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="126102">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01956474</url>
  </required_header>
  <id_info>
    <org_study_id>CXL-04</org_study_id>
    <nct_id>NCT01956474</nct_id>
  </id_info>
  <brief_title>A Study of Collagen Crosslinking With Ultraviolet-A in Asymmetric Corneas</brief_title>
  <official_title>Collagen Crosslinking With Ultraviolet-A in Asymmetric Corneas</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Cxlusa</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Cxlusa</source>
  <oversight_info>
    <authority>United States: Food and Drug Administration</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate the efficacy of ultraviolet-A (UVA)-induced
      cross-linking of corneal collagen (CXL) as a method to increase the biomechanical and
      biochemical stability of the cornea by inducing additional cross-links within or between
      collagen fibers using UVA light and the photo- mediator riboflavin.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>January 2013</start_date>
  <completion_date type="Anticipated">June 2015</completion_date>
  <primary_completion_date type="Anticipated">January 2015</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <study_design>Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>Change in Best Spectacle Corrected Visual Acuity (BSCVA)</measure>
    <time_frame>6-9 months</time_frame>
    <safety_issue>Yes</safety_issue>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change in Uncorrected Visual Acuity (UCVA)</measure>
    <time_frame>6-9 months</time_frame>
    <safety_issue>Yes</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Corneal topography</measure>
    <time_frame>6-9 months</time_frame>
    <safety_issue>Yes</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Manifest Refraction</measure>
    <time_frame>6-9 months</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Keratometry on topography and Pentacam</measure>
    <time_frame>6-9 months</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Wavefront Refraction and aberrations</measure>
    <time_frame>6-9 months</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">1500</enrollment>
  <condition>Keratoconus</condition>
  <arm_group>
    <arm_group_label>Corneal Cross-linking</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>ultraviolet-A (UVA)-induced cross-linking of corneal collagen (CXL) using UVA light and the photo- mediator riboflavin</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Theralight crosslinking and Riboflavin</intervention_name>
    <arm_group_label>Corneal Cross-linking</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. 8 years of age or older

          2. Having at least one of the following conditions:

               -  Keratoconus

               -  Post-LASIK ectasia

               -  Pellucid marginal degeneration

               -  Forme fruste pellucid marginal degeneration

               -  FFKC

               -  History of Radial Keratotomy with fluctuating vision.

               -  Terrien's Marginal Degeneration

          3. Signed written informed consent and/or assent

          4. Likely to complete all study visits

          5. Minimum corneal thickness of at least 250 microns measured by ultrasound or Pentacam
             for all indications other than Terrien's. For Terrien's, the minimal corneal
             thickness should be consistent with the surgeon's best surgical judgment.

        Exclusion Criteria:

          1. Severe corneal scarring that markedly affects vision

          2. Contraindications to any study medications or their components

          3. Pregnancy or breast feeding

          4. Active Herpes Corneal Disease
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>8 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Center for Excellence in Eye Care</name>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <zip>33176</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Matty Infante</last_name>
      <email>mattyceec@bellsouth.net</email>
    </contact>
    <investigator>
      <last_name>William Trattler, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Stulting Research Center at Woolfson Eye Institute</name>
      <address>
        <city>Atlanta</city>
        <state>Georgia</state>
        <zip>30328</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Debbie Dichiara</last_name>
      <email>ddichiara@woolfsoneye.com</email>
    </contact>
    <investigator>
      <last_name>Robert Stulting, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>TLC Laser Eye Center</name>
      <address>
        <city>Rockville</city>
        <state>Maryland</state>
        <zip>20852</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Stephanie Merritt</last_name>
      <email>sismerritt@gmail.com</email>
    </contact>
    <investigator>
      <last_name>Levy Marc, OD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Talamo Hatch Laser Eye Consultants, LLC</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02451</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Migdali Rivera</last_name>
      <email>MRivera@lasikofboston.com</email>
    </contact>
    <investigator>
      <last_name>Johnathan Talamo, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Cleveland Eye Clinic</name>
      <address>
        <city>Brecksville</city>
        <state>Ohio</state>
        <zip>44141</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Karen Keaton</last_name>
      <email>kkeaton@clevelandeyeclinic.com</email>
    </contact>
    <investigator>
      <last_name>Shamik Bafna, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>TLC Laser Eye Center</name>
      <address>
        <city>Fairfax</city>
        <state>Virginia</state>
        <zip>22031</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Stephanie Merritt</last_name>
      <email>sismerritt@gmail.com</email>
    </contact>
    <investigator>
      <last_name>Marc Levy, OD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>May 2014</verification_date>
  <lastchanged_date>May 7, 2014</lastchanged_date>
  <firstreceived_date>September 27, 2013</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>keratoconus</keyword>
  <keyword>cross-linking</keyword>
  <keyword>Post-LASIK ectasia</keyword>
  <keyword>Pellucid marginal degeneration</keyword>
  <keyword>Forme fruste pellucid marginal degeneration</keyword>
  <keyword>FFKC</keyword>
  <keyword>Radial Keratotomy</keyword>
  <keyword>Terrien's Marginal Degeneration</keyword>
  <is_fda_regulated>Yes</is_fda_regulated>
  <is_section_801>Yes</is_section_801>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Keratoconus</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Riboflavin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
